

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 14 2008

Medical Technology Systems, Inc. % Ellis K. Nam, M.D. 6101 N. Sheridan Road, Suite #40D Chicago, IL 60660

Re: K063175

Trade/Device Name: iPUPc (Intelligent Pressure Ulcer Prevention Cushion)

Regulatory Class: Unclassified

Product Code: MOC

Dated: December 14, 2007 Received: December 18, 2007

Dear Dr. Nam:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Ellis K. Nam, M.D.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson

Mark of Melkerson

Director

Division of General, Restorative and Neurological Devices
Office of Device Evaluation
Center for Devices and

Radiological Health

Enclosure

8. Statement of Indications for Use

510(k) Number (if known): <u>K063175</u>
Device Name: iPUPc (Intelligent Pressure Ulcer Prevention Cushion)
Indications for Use:
The <i>iPUPc</i> is appropriate for use by any wheelchair user, who requires regular periodic positioning changes without the aid of an attendant. These regular, periodic positioning changes are needed for, but not limited to:
Pressure relief or reduction by shifting the user's body weight from the buttocks to the thighs and the lower back.
The <i>iPUPc</i> seating system could provide pressure relief by postural change for persons having the following condition or injury: an existing pressure sore, or ar individual at extreme risk of developing a pressure sore.
Any individual who needs pressure relief through regular periodic positional changes, who is unable to do so independently, can accomplish this through the iPUPc device.
Prescription Usex AND/OR Over-The-Counter Usex (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)

Division of General, Restorative,

510(k) Number K063 175

and Neurological Devices